长效注射剂市场：依适应症、分子类型、给药途径、器械类型、製剂技术、病患类型、最终用户、分销管道、支付方和地区划分

预计到 2025 年，长效注射剂市场规模将达到 191.6 亿美元，到 2032 年将达到 453.6 亿美元，2025 年至 2032 年的复合年增长率为 13.1%。

全球长效注射剂（缓释注射剂）市场是製药业中一个快速发展的细分领域，其特点是采用创新的药物递送系统，旨在提高患者依从性和治疗效果。长效注射剂（LAI）是一种特殊配方，可透过肌肉注射、皮下注射或其他注射途径给药，可在数週至数月的较长时间内持续释放药物。这些先进的药物传递机制无需频繁给药，从而解决了与药物依从性相关的重大挑战，尤其是在思觉失调症、双相情感障碍、糖尿病和爱滋病治疗等慢性疾病中。

该市场涵盖多种技术平台，包括微球、脂质体、植入和缓释製剂，利用先进的药物传递技术实现可控且持续的治疗效果。慢性病发病率的上升、对以患者为中心的医疗保健解决方案的日益重视以及对个性化医疗需求的增长，正推动着长效注射剂（LAI）研发领域的大量投资。製药公司日益认识到缓释製剂的商业性潜力，它可以透过改善患者疗效、降低医疗成本和增强市场差异化来提供竞争优势。复杂的生产流程、严格的监管要求和大量的研发投入，使得缓释製剂成为多种疾病领域现代治疗策略的关键组成部分。

市场动态

全球长效注射剂市场由多个关键驱动因素推动，这些因素正在从根本上改变药物治疗模式和患者照护方法。其中一个关键成长要素源自于解决药物依从性差这项重大挑战的需求。药物依从性差影响约40-60%的慢性疾病患者，导致数十亿美元的医疗成本增加和治疗效果下降。长效注射剂透过持续给药，无需每日给药，提供了强烈的解决方案，这对精神疾病、糖尿病和感染疾病患者尤其有利。慢性病盛行率的上升、全球人口老化以及人们对个人化医疗日益增长的认识，都为长效注射剂生产商创造了巨大的市场机会。

然而，该市场面临着许多限制因素，包括高昂的研发成本、复杂的生产流程以及严格的监管核准流程，这些都可能将研发週期延长数年。此外，製剂稳定性、注射部位反应和剂量柔软性等方面的技术挑战也阻碍了市场扩张。

此外，与口服药物相比，长效注射剂（LAI）较高的初始治疗费用以及医师对LAI给药技术的不熟悉程度也可能阻碍其推广应用。儘管存在这些挑战，但随着药物递送系统技术的进步、应用范围的拓展以及医疗专业人员对基于价值的医疗模式日益重视，市场仍蕴藏着巨大的机会。可生物降解聚合物、奈米技术递送系统和联合治疗的出现，正在为市场成长开闢新的途径；同时，新兴市场投资的增加和医疗基础设施的改善，也为行业相关人员开闢了新的收入来源。

本报告的主要特点

• 本报告对全球长效注射剂市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模和复合年增长率，以 2024 年为基准年。
• 它还重点介绍了各个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
• 它还提供了有关市场驱动因素、限制因素和机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的关键见解。
• 根据公司概况、产品系列、主要亮点、财务表现和策略等参数，对全球长效注射剂市场的主要企业进行了分析。
• 本报告提供的见解将使负责人和企业经营团队能够就未来的产品发布、合作关係、市场扩张和行销策略做出明智的决策。
• 《全球长效注射剂市场》报告面向该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过各种策略矩阵来分析全球长效注射剂市场，从而更轻鬆地做出决策。

目录

第一章 分析目标和先决条件

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章：市场动态、监理及趋势分析

• 市场动态
• 司机
• 抑制因素
• 机会
• 影响分析
• 重大进展
• 监管情景
• 产品上市/核准
• PEST分析
• 波特五力分析
• 企业合併情景
• 产业趋势

4. 全球长效注射剂市场（依适应症划分）（2020-2032 年）

• 精神疾病
• 神经系统疾病
• 内分泌和代谢紊乱
• 感染疾病
• 女性健康
• 肿瘤科和支持性治疗
• 疼痛、成瘾和中枢神经系统支持性护理
• 其他慢性疾病

5. 全球长效注射剂市场（依分子类型划分）（2020-2032 年）

• 小分子药物
• 胜肽和胜肽类似物
• 蛋白质和生物製药
• 基于核酸的基因修饰剂
• LAI型疫苗/免疫疗法
• 其他分子类型

6. 全球长效注射剂市场依给药途径划分（2020-2032 年）

• 肌肉内注射（IM）
• 皮下（SC）
• 玻璃体内注射
• 关节内
• 鞘内/硬膜外
• 其他特殊肠外给药途径

7. 全球长效注射剂市场（依器材类型划分）（2020-2032 年）

• 预填充式注射器
• 自动注射器
• 管瓶和注射器套装
• 植入套件
• 长效注射笔系统

8. 全球长效注射剂市场依製剂技术划分（2020-2032 年）

• 基于微球的储库
• 原位成型仓库
• 脂质体配方
• 奈米悬浮液
• 聚合物结合长效注射剂
• 植入式长效注射装置
• 油基注射库
• 长效注射用结晶质悬浮液

9. 全球长效注射剂市场（依病患类型划分）（2020-2032 年）

• 成人
• 老年人
• 儿童

第十章 全球长效注射剂市场（依最终用户划分）（2020-2032 年）

• 医院
• 专科诊所
• 社区医疗中心
• 门诊手术中心
• 居家医疗/自我管理计划
• 政府和公共卫生项目

第十一章 全球长效注射剂市场依通路划分（2020-2032 年）

• 零售药房
• 医院药房
• 网路药房

12. 全球长效注射剂市场（依支付方划分）（2020-2032 年）

• 公共机构
• 私人的

第十三章 全球长效注射剂市场（按地区划分）（2020-2032 年）

• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中非

第十四章 竞争格局

• Eli Lilly and Company
• Novo Nordisk A/S
• Janssen Pharmaceuticals（Johnson and Johnson）
• AstraZeneca
• Pfizer Inc
• GlaxoSmithKline plc
• ViiV Healthcare
• Merck and Co Inc
• Takeda Pharmaceutical Company
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Boehringer Ingelheim
• Amgen Inc
• Roche
• Sun Pharmaceutical Industries

第十五章 分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map (COM)

第十六章 参考文献与分析方法

• 参考
• 分析方法
• 关于 Coherent Market Insights

Long Acting Injectables Market is estimated to be valued at USD 19.16 Bn in 2025 and is expected to reach USD 45.36 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.1% from 2025 to 2032.

The global long acting injectables market represents a rapidly evolving segment of the pharmaceutical industry, characterized by innovative drug delivery systems designed to enhance patient compliance and therapeutic outcomes. Long acting injectables (LAIs) are specialized pharmaceutical formulations administered via intramuscular, subcutaneous, or other injection routes, providing sustained drug release over extended periods ranging from weeks to months. These advanced delivery mechanisms eliminate the need for frequent dosing, addressing critical challenges associated with medication adherence, particularly in chronic conditions such as schizophrenia, bipolar disorder, diabetes, and HIV treatment.

The market encompasses various technological platforms including microspheres, liposomes, implants, and depot formulations, utilizing sophisticated drug delivery technologies to achieve controlled and sustained therapeutic effects. The growing prevalence of chronic diseases, increasing focus on patient-centric healthcare solutions, and rising demand for personalized medicine are driving significant investments in LAI research and development. Pharmaceutical companies are increasingly recognizing the commercial potential of long acting formulations, as they offer competitive advantages through improved patient outcomes, reduced healthcare costs, and enhanced market differentiation. The market landscape is characterized by complex manufacturing processes, stringent regulatory requirements, and substantial research and development investments, positioning LAIs as a critical component of modern therapeutic strategies across multiple disease areas.

Market Dynamics

The global long acting injectables market is propelled by several key drivers that are fundamentally reshaping pharmaceutical treatment paradigms and patient care approaches. The primary growth driver stems from the critical need to address medication non-adherence, which affects approximately 40-60% of patients with chronic conditions, resulting in billions of dollars in healthcare costs and compromised therapeutic outcomes. Long acting injectables offer a compelling solution by ensuring consistent drug delivery and eliminating daily dosing requirements, particularly benefiting patients with psychiatric disorders, diabetes, and infectious diseases. The increasing prevalence of chronic diseases, aging global population, and growing awareness of personalized medicine are creating substantial market opportunities for LAI manufacturers.

However, the market faces significant restraints including high development costs, complex manufacturing processes, and stringent regulatory approval pathways that can extend development timelines by several years. The technical challenges associated with formulation stability, injection site reactions, and dose flexibility limitations also present barriers to market expansion.

Additionally, higher initial treatment costs compared to oral medications and limited physician familiarity with LAI administration techniques can impede adoption rates. Despite these challenges, the market presents remarkable opportunities through technological advancements in drug delivery systems, expanding applications across therapeutic areas, and increasing healthcare focus on value-based care models. The emergence of biodegradable polymers, nanotechnology-based delivery systems, and combination therapy approaches are creating new avenues for market growth, while growing investments in emerging markets and increasing healthcare infrastructure development are opening additional revenue streams for industry participants.

Key Features of the Study

• This report provides in-depth analysis of the global long acting injectables market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global long acting injectables market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eli Lilly and Company, Novo Nordisk A/S, Janssen Pharmaceuticals (Johnson and Johnson), AstraZeneca, Pfizer Inc, GlaxoSmithKline plc, ViiV Healthcare, Merck and Co Inc, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd, Sanofi, Boehringer Ingelheim, Amgen Inc, Roche, and Sun Pharmaceutical Industries
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global long acting injectables market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global long acting injectables market

Market Segmentation

• Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Psychiatric disorders
  • Neurological disorders
  • Endocrine and metabolic disorders
  • Infectious diseases
  • Women's health
  • Oncology and supportive care
  • Pain, addiction and CNS supportive care
  • Other chronic diseases
• Molecule Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Small-molecule drugs
  • Antipsychotics
  • Hormonal agents (e.g., contraceptives)
  • Analgesics and addiction therapies
  • Other small-molecule LAIs
  • Peptides and peptide analogues
  • GLP-1 and related incretin mimetics
  • Other therapeutic peptides
  • Proteins and biologics
  • Monoclonal antibodies
  • Fusion proteins and recombinant hormones
  • Long-acting growth factors and cytokines
  • Nucleic acid-based and gene-modifying agents
  • Oligonucleotides
  • Gene therapy-linked depot systems
  • Vaccines and immunotherapies in LAI formats
  • Other molecule types
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Intramuscular (IM)
  • Subcutaneous (SC)
  • Intravitreal
  • Intra-articular
  • Intrathecal and epidural
  • Other specialized parenteral routes
• Device Format Insights (Revenue, USD Bn, 2020 - 2032)
  • Pre-filled Syringes
  • Auto-injectors
  • Vial and Syringe Kits
  • Implant Kits
  • Pen-injector LAI Systems
• Formulation Technology Insights (Revenue, USD Bn, 2020 - 2032)
  • Microsphere-based Depots
  • In-situ Forming Depots
  • Liposomal LAIs
  • Nano-suspensions
  • Polymer-conjugated LAIs
  • Implantable LAI Devices
  • Oil-based Injectable Depots
  • Long-acting Injectable Crystalline Suspensions
• Patient Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Adult
  • Geriatric
  • Pediatric
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Community Health Centers
  • Ambulatory Surgical Centers
  • Home-care/Self-administration Programs
  • Government and Public Health Programs
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
• Payer Insights (Revenue, USD Bn, 2020 - 2032)
  • Public
  • Private
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Janssen Pharmaceuticals (Johnson and Johnson)
  • AstraZeneca
  • Pfizer Inc
  • GlaxoSmithKline plc
  • ViiV Healthcare
  • Merck and Co Inc
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Boehringer Ingelheim
  • Amgen Inc
  • Roche
  • Sun Pharmaceutical Industries

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Long Acting Injectables Market, By Indication
  • Global Long Acting Injectables Market, By Molecule Type
  • Global Long Acting Injectables Market, By Route of Administration
  • Global Long Acting Injectables Market, By Device Format
  • Global Long Acting Injectables Market, By Formulation Technology
  • Global Long Acting Injectables Market, By Patient Type
  • Global Long Acting Injectables Market, By End User
  • Global Long Acting Injectables Market, By Distribution Channel
  • Global Long Acting Injectables Market, By Payer
  • Global Long Acting Injectables Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Long Acting Injectables Market, By Indication, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Psychiatric disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neurological disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Endocrine and metabolic disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Infectious diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Women's health
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oncology and supportive care
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pain, addiction and CNS supportive care
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other chronic diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Long Acting Injectables Market, By Molecule Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Small-molecule drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Antipsychotics
    • Hormonal agents (e.g., contraceptives)
    • Analgesics and addiction therapies
    • Other small-molecule LAIs
• Peptides and peptide analogues
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • GLP-1 and related incretin mimetics
    • Other therapeutic peptides
• Proteins and biologics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Monoclonal antibodies
    • Fusion proteins and recombinant hormones
    • Long-acting growth factors and cytokines
• Nucleic acid-based and gene-modifying agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Oligonucleotides
    • Gene therapy-linked depot systems
• Vaccines and immunotherapies in LAI formats
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other molecule types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Long Acting Injectables Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Intramuscular (IM)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Subcutaneous (SC)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravitreal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intra-articular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intrathecal and epidural
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other specialized parenteral routes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Long Acting Injectables Market, By Device Format, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pre-filled Syringes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Auto-injectors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Vial and Syringe Kits
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Implant Kits
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pen-injector LAI Systems
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Long Acting Injectables Market, By Formulation Technology, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Microsphere-based Depots
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• In-situ Forming Depots
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Liposomal LAIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Nano-suspensions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Polymer-conjugated LAIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Implantable LAI Devices
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oil-based Injectable Depots
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Long-acting Injectable Crystalline Suspensions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Long Acting Injectables Market, By Patient Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Long Acting Injectables Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Community Health Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Home-care/Self-administration Programs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Government and Public Health Programs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Long Acting Injectables Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Long Acting Injectables Market, By Payer, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Public
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Private
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

13. Global Long Acting Injectables Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

14. Competitive Landscape

• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novo Nordisk A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Janssen Pharmaceuticals (Johnson and Johnson)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• ViiV Healthcare
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck and Co Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Roche
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

15. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

16. References and Research Methodology

• References
• Research Methodology
• About us